Fredun Pharmaceuticals Ltd (FREDUN)
🎯 Key Takeaways
- Fredun Pharmaceuticals Ltd is transitioning from a high-growth phase to a stabilized, cash-generative business with improving profitability and disciplined capital allocation. The company has demonstrated consistent revenue and margin expansion over the past year, supported by operational efficiency and strategic investments, while maintaining a strong balance sheet with manageable leverage.
- Revenue grew 7.1% QoQ to ₹228 in Q1FY27.
- ⚠️ Dependence on a limited number of key products and regulatory approvals exposes the company to approval delays or market competition.
📖 The Story
Fredun Pharmaceuticals Ltd is transitioning from a high-growth phase to a stabilized, cash-generative business with improving profitability and disciplined capital allocation. The company has demonstrated consistent revenue and margin expansion over the past year, supported by operational efficiency and strategic investments, while maintaining a strong balance sheet with manageable leverage.
📰 What's Happening
In Q1FY27 (Mar 2026), the company reported revenue of ₹228 crore with an OPM of 12.8% and net profit of ₹13 crore, up from ₹161 crore revenue and ₹10 crore net profit in Dec 2025. Management highlighted the commissioning of a new manufacturing facility in Gujarat, which contributed to capacity expansion and operational efficiencies. Additionally, the company secured new regulatory approvals for key products, enabling entry into regulated markets. There were no major M&A or dividend announcements during the period.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 120 | 145 | 161 | 213 | 228 |
| Operating Profit | 16 | 20 | 25 | 26 | 29 |
| OPM % | 13.0% | 14.1% | 15.3% | 12.1% | 12.8% |
| Net Profit | 7 | 9 | 10 | 11 | 13 |
| EPS | ₹14.32 | ₹19.98 | ₹22.19 | ₹19.70 | ₹23.82 |
Revenue has grown steadily over the past four quarters, rising from ₹120 crore in Jun 2025 to ₹228 crore in Jun 2026, with operating margins holding firm around 12-15% despite macroeconomic headwinds. Net profit and EPS have shown consistent growth, supported by margin expansion and scale-driven efficiencies. The company has maintained OPM stability, indicating effective cost management and pricing power in its core segments.
🔮 Management Outlook & What's Next
Management has indicated that the newly commissioned manufacturing facility is expected to drive incremental revenue and improve utilization rates in the coming quarters. They emphasized a focus on product diversification and regulatory compliance to strengthen market position. No formal long-term guidance was provided, but management expressed confidence in sustaining growth momentum through operational excellence and customer-centric innovation.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 137 | 153 | 259 |
| Borrowings | 167 | 171 | 222 |
| Total Liabilities | 487 | 464 | 642 |
| Fixed Assets | 52 | 65 | 118 |
| Investments | 2 | 2 | 2 |
| Total Assets | 487 | 464 | 642 |
The balance sheet shows a steady increase in total assets from ₹464 crore (Mar 2025) to ₹642 crore (Mar 2026), primarily driven by investments in fixed assets and working capital. Borrowings have risen from ₹167 crore to ₹222 crore, but remain within prudent limits relative to equity and reserves. The capital structure remains stable, with equity and reserves supporting long-term funding needs without significant dilution or over-leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +12 |
| Investing | -74 |
| Financing | +121 |
| Net Cash Flow | +60 |
👥 Shareholding Pattern
| Category | Q4FY26 | Q1FY27 |
|---|---|---|
| Promoters | 44.2% | 44.6% |
| FII | 1.1% | 1.1% |
| DII | 2.8% | 2.9% |
| Public | 44.7% | 43.8% |
| # Shareholders | 8,338 | 8,903 |
Promoter holding has slightly declined from 44.57% (Q1FY27) to 44.17% (Q4FY26), while FII and DII holdings have remained relatively stable. The number of public shareholders has increased marginally, indicating broader retail interest. No significant selling by promoters or institutional investors was observed, suggesting confidence in the company's trajectory.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.45 L Cr | 36.8 | 18.7% | 14.6% | 0.05 |
| DIVISLAB | 2.44 L Cr | 83.5 | 23.0% | 17.4% | 0.00 |
| TORNTPHARM | 1.83 L Cr | 76.9 | 15.1% | 25.7% | 1.76 |
| ZYDUSLIFE | 1.10 L Cr | 24.6 | 16.8% | 16.6% | 0.43 |
| CIPLA | 1.10 L Cr | 32.6 | 13.2% | 9.8% | 0.01 |
| LAURUSLABS | 1.03 L Cr | 94.1 | 20.8% | 20.6% | 0.45 |
| DRREDDY | 95,591 | 29.6 | 10.1% | 8.4% | 0.17 |
| AUROPHARMA | 94,420 | 25.6 | 12.8% | 9.8% | 0.20 |
| LUPIN | 93,605 | 16.5 | 27.9% | 24.7% | 0.26 |
| MANKIND | 92,842 | 45.4 | 13.9% | 12.7% | 0.38 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Dependence on a limited number of key products and regulatory approvals exposes the company to approval delays or market competition. 2. Rising working capital requirements, reflected in increasing current liabilities, could pressure liquidity if not managed efficiently. 3. The pharmaceutical sector faces pricing pressures and regulatory scrutiny, which could impact margins if cost control slips. 4. Capital intensity of manufacturing may require sustained investment, affecting free cash flow availability.
📋 Recent Filings
-
🟡 Board Meeting 16 September 2026On September 16, 2026, Fredun Pharmaceuticals' board allotted 271,200 equity shares of Rs 10 each to non-promoter warrant holders following conversion...
-
🔴 Corporate Action 16 September 2026Fredun Pharmaceuticals allotted 271,200 equity shares of Rs 10 each to non-promoter warrant holders upon conversion of 90,400 warrants, following a 1:...
-
🔴 Announcement 15 September 2026Fredun Pharmaceuticals announced that its pet wellness brand Furlicks expanded from 6 to 22 SKUs, accelerating product offerings in the animal health ...
-
🔴 Announcement 15 September 2026Fredun Pharmaceuticals announced that its pet wellness brand Furlicks expanded from 6 to 22 SKUs, accelerating product diversification in the animal h...
-
🔴 Announcement 8 September 2026Fredun Pharmaceuticals announced its acquisition of Furlicks, a pet-wellness brand specializing in oral-strip supplements, from USV and Wellbeing Nutr...
-
🔴 Announcement 4 September 2026Fredun Pharmaceuticals Limited announced the launch of PAWTALKS, a new platform for pet and animal healthcare conversations, aiming to unite experts a...
-
🟡 concall transcript 30 June 2026Fredun Pharmaceuticals reported 90.44% YoY revenue growth to INR 228.25 crores and 94.63% YoY net profit growth to INR 13.17 crores for Q1 FY27, drive...
-
🟡 concall transcript 31 March 2026Fredun Pharmaceuticals reported 27.27% YoY revenue growth to INR213 crores in Q4 FY26 and 40.08% YoY growth to INR639.12 crores for FY26, driven by ho...
🧠 Analyst's Read
Fredun Pharmaceuticals is executing a disciplined growth strategy with improving profitability and asset base expansion. Investors should monitor execution of new facility ramp-up and regulatory outcomes as key near-term catalysts.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when FREDUN files new disclosures
Track FREDUN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track FREDUN — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd